Clinical trials
Lung Cancer Stage III clinical trials
Below are recruiting lung cancer stage iii clinical trials, each written for real people, not researchers. We’re tracking 387 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05339568Recruiting
Smartphone support program for people with advanced lung cancer
This trial tests a “whole process follow-up” care plan, using a smartphone, to support people with non-small cell lung cancer from diagnosis through treatment and follow-up. It may help you manage care steps more smoothly if you’re not a candidate for curative (radical) treatment or don’t want surgery.
Jinan, ShandongAges 18 years+ - NCT05236114Recruiting
Study of blood and tumor tests for lung cancer treatment
This study looks at how tumor and blood biomarker results can guide treatment for people with non-small cell lung cancer (NSCLC). Depending on the cancer stage, it may follow standard-of-care treatment plans around surgery or first-line immunotherapy.
Birmingham, AlabamaAges 18 years+ - NCT05366478RecruitingPhase 1
LM103 for advanced solid tumors using donated immune cells
This Phase 1 study tests LM103 to treat advanced cancers that are not responding to standard treatment. It also looks at whether enough tumor tissue can be collected for immune cell testing, and focuses on safety at first.
TianjinAges 18 years+ - NCT05724004Recruiting
Alectinib then targeted radiation for ALK-positive lung cancer
This trial tests giving alectinib first, then adding targeted radiation to remaining spots of cancer in people with ALK-rearranged advanced non-small cell lung cancer. It aims to control the cancer after an initial response and help keep disease from progressing.
StockholmAges 20 years+ - NCT06171750RecruitingPhase 1
Study of ANK-101 for advanced solid tumors
This trial tests a new drug, ANK-101, injected directly into tumors to help fight advanced solid tumors that have spread or can't be treated with standard therapies. It may be an option if you have a tumor that can be reached for injection.
Bethesda, MarylandAges 18 years+ - NCT06188650Recruiting
New drug combo for advanced lung cancer after two treatments fail
This trial tests a combination of a targeted chemotherapy bead injection into lung arteries, an oral anti-cancer drug, and an immunotherapy for advanced non-small cell lung cancer that has not responded to two prior treatments. It aims to see if this triple approach can help patients who have limited options left.
Ningbo, ZhejiangAges 18 years+ - NCT06239727RecruitingPhase 3
Reduced-dose radiotherapy for stage III nasopharyngeal cancer based on response
This trial tests whether a lower dose of radiation can safely treat stage III nasopharyngeal cancer if you have already responded well to initial chemotherapy plus immunotherapy (Camrelizumab). The goal is to reduce side effects while still controlling the cancer.
Fuzhou, FujianAges 18–65 - NCT06248606RecruitingPhase 2
Adagrasib with brain radiation for KRAS G12C lung cancer with brain mets
This study tests a targeted pill (adagrasib) combined with focused radiation to the brain (SRS) for people with KRAS G12C-mutated lung cancer that has spread to the brain. The goal is to see if this combination can control brain tumors while treating the rest of the body.
Columbus, OhioAges 18 years+ - NCT06295926RecruitingPhase 2
Testing a new immunotherapy with chemo-radiation for limited-stage small cell lung cancer
This trial is testing whether adding the immunotherapy drug serplulimab to standard chemotherapy and radiation can help people with limited-stage small cell lung cancer. It is for those who have not had any previous treatment for their cancer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06369181Recruiting
Study on cell changes in lung cancer with RB1/TP53 gene changes
This trial looks at what happens when certain types of non-small cell lung cancer—those with changes in the RB1 and TP53 genes—start to change into another type of lung cancer after treatment. It may help find better ways to treat this specific kind of cancer in the future.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06388031RecruitingPhase 2
Re-trying immunotherapy for advanced lung cancer after long-term success
This trial tests whether giving immunotherapy again can help people with advanced non-small cell lung cancer whose disease stayed stable for at least 2 years on their first immunotherapy but then started growing. It aims to see if a second course of treatment can work again.
BeijingAges 18–80 - NCT06403111RecruitingPhase 2
FMT with immunotherapy and chemotherapy for advanced lung cancer
This trial tests a combination of fecal microbiota transplantation (FMT), immunotherapy, and chemotherapy as a first treatment for advanced non-small cell lung cancer that does not have a driver gene mutation. The goal is to see if adding FMT can help the immune system fight the cancer better.
ChangzhouAges 18–80 - NCT06448572RecruitingPhase 1/Phase 2
EXL01 and nivolumab for immunotherapy-resistant lung cancer
This trial tests an investigational microbiome therapy (EXL01) combined with nivolumab (an immunotherapy) for people with advanced non-small cell lung cancer whose cancer continued to grow after standard immunotherapy and chemotherapy. The goal is to see if adding EXL01 can help the immune system fight the cancer again.
LilleAges 18 years+ - NCT06467617RecruitingPhase 2
Immunotherapy and chemo before and after lung cancer surgery
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy and another drug (recaticimab) before and after surgery for people with stage II or III lung cancer that can be removed. The goal is to see if this approach helps shrink tumors and improves outcomes.
Beijing, Beijing MunicipalityAges 18–75 - NCT06485544RecruitingPhase 2
Immunotherapy before surgery for small cell lung cancer
This trial tests adding a drug called adebrelimab (a type of immunotherapy) before surgery for people with early-stage small cell lung cancer that can be removed. The goal is to see if it helps shrink the tumor and improve outcomes.
Xi'an, ShannxiAges 18–75 - NCT07593248Recruiting
Real-World Lung Cancer Outcomes With Targeted Drug Therapy in China
This study looks at how well patients with early-stage lung cancer (that has been surgically removed) do when treated with a targeted drug called EGFR-TKI to prevent cancer from coming back. Researchers will track actual patient outcomes in China from 2023 to 2026.
GuangzhouAges 18 years+ - NCT06496048RecruitingPhase 3
Testing lurbinectedin for small cell lung cancer that has returned
This trial compares a new drug combination (lurbinectedin with or without irinotecan) against the standard treatment (topotecan) for people whose small cell lung cancer has come back after initial chemotherapy. It aims to see if the new options work better.
Jilin CityAges 18 years+ - NCT06534489Recruiting
Surgery for lung cancer after chemo or targeted therapy
This trial tests whether combining chemo or targeted therapy before surgery can help people with non-small cell lung cancer that may require removing a whole lung. We want to see if this approach makes the surgery safer and more effective.
ShanghaiAges 18–75 - NCT06545747RecruitingPhase 3
MRI-guided radiation for advanced lung cancer
This trial tests a new way of giving radiation therapy for advanced lung cancer that cannot be surgically removed. It uses MRI scans to guide and adjust the radiation dose, which may help target the tumor more precisely and reduce side effects.
GuangzhouAges 18–75 - NCT06581419RecruitingPhase 1/Phase 2
Testing IAP0971 in advanced solid tumors and lung cancer
This trial tests a new drug called IAP0971 for people with advanced solid tumors or a specific type of lung cancer. It may help if your cancer has not responded to other treatments or if you have PD-L1-positive lung cancer that hasn't been treated yet.
Beijing, Beijing MunicipalityAges 18–75 - NCT06617416RecruitingPhase 3
AK104 for locally advanced lung cancer after chemoradiotherapy
This trial tests a new immunotherapy drug, AK104, for people with stage III non-small cell lung cancer that cannot be removed with surgery. It is for those who have finished chemoradiotherapy and have not gotten worse.
JinanAges 18 years+ - NCT06749886RecruitingPhase 2
Tislelizumab plus chemo for advanced lung cancer after prior immunotherapy
This trial tests a drug called Tislelizumab (an immunotherapy) combined with chemotherapy for people with advanced NSCLC who have already been helped by a different immunotherapy. It's a second-line option for those who did well on their first immunotherapy but now need another treatment.
ShanghaiAges 18 years+ - NCT06805825RecruitingPhase 1
Study of NN3201 for advanced cancers with c-Kit
This trial tests a new drug, NN3201, that targets a protein called c-Kit found on some cancer cells. It may be an option for people with certain advanced solid tumors, including GIST, small cell lung cancer, or other c-Kit-positive cancers, who have already tried standard treatments or cannot take them.
Ann Arbor, MichiganAges 18 years+ - NCT06865339RecruitingPhase 2
Radiation plus immunotherapy for advanced lung cancer
This trial tests whether adding two immunotherapy drugs (cemiplimab and fianlimab) to standard radiation and chemotherapy can help treat locally advanced non-small cell lung cancer that hasn't been treated before.
The Bronx, New YorkAges 18 years+
Hear when a new Lung Cancer Stage III trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer stage iii?
- Yes. Clin2 currently lists 387 recruiting lung cancer stage iii studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer stage iii trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer stage iii trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Non-small Cell Lung Cancer Stage III
- Stage III Lung Cancer AJCC v8
- Nonsmall Cell Lung Cancer Stage III
- Unresectable Stage III Non-small Cell Lung Cancer
- Small Cell Lung Cancer Extensive Stage
- Stage IV Lung Cancer AJCC v8
- Anatomic Stage III Breast Cancer AJCC v8
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.